In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cardiovascular Pharmacotherapy

Position Papers and Consensus Documents from the ESC Working Group on Cardiovascular Pharmacotherapy

ESC working group position paper on myocardial infarction with non-obstructive coronary arteries

, , , , , , , , , , , , , on behalf of the WG on Cardiovascular Pharmacotherapy
European Heart Journal DOI: - First published online: 28 April 2016

Read the full text

Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs

Review and Position Paper By The Working Group For Cardiovascular Pharmacotherapy of The European Society Of Cardiology

Read the full text

Authors:  Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, Stefan Agewall, Juan Carlos Kaski, Keld Kjeldsen, Basil S. Lewis, Christian Torp-Pedersen

European Heart Journal - Cardiovascular Pharmacotherapy. doi: 10.1093/ehjcvp/pvv054 108-118. First published online: 16 March 2016

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management

A joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Read the full text 

Authors:  Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S.

Heart J. 2015 Dec 24. doi 10.1093/eurheartj/ehv676 First published online: 24 December 2015

Gender differences in the effect of cardiovascular drugs

A position document of the Working Group on Pharmacology and Drug Therapy of the ESC

Read the full text 

Authors: Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J.

Eur Heart J. 2015 Oct 21;36(40):2677-80. doi: 10.1093/eurheartj/ehv161. First published online: 6 May 2015

Expert Position Paper on the use of proton pump inhibitors in patients with cardiovascular disease

Read the full text 

Authors: Stefan Agewall1, Cattaneo, J.P. Collet, F. Andreotti, G.Y.H. Lip,F.W.A. Verheugt, K. Huber, E.L. Grove, J. Morais, S. Husted, S. Wassmann, G. Rosano, D. Atar1, A. Pathak, K. Kjeldsen, and R.F. Storey

Eur Heart J (2013) doi: 10.1093/eurheartj/eht042 First published online: February 20, 2013

Introduction: The ESC NSTEMI and STEMI guidelines1,2 and an ACCF/ACG/AHA consensus document3 recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS) (ESC Class 1A recommendation), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metabolite.
The aim of this position paper is to review the pharmacokinetic background of the interactions between these drugs, and their consequences on clinical outcomes, and to present suggestions for management of this important issue…